Mallinckrodt's gross profit for the
three
months ended in Sep. 2023 was $151 Mil. Mallinckrodt's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $356 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Mallinckrodt's gross profit for the
three
months ended in Sep. 2023 was $151 Mil. Mallinckrodt's Revenue for the
three
months ended in Sep. 2023 was $497 Mil. Therefore, Mallinckrodt's Gross Margin % for the quarter that ended in Sep. 2023 was 30.34%.
Mallinckrodt had a gross margin of 30.34% for the quarter that ended in Sep. 2023 => Competition eroding margins
During the past 12 years, the highestGross Margin % of Mallinckrodt was 55.52%. The lowest was 18.87%. And the median was 48.02%.
Mallinckrodt Gross Profit Historical Data
The historical data trend for Mallinckrodt's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Mallinckrodt's Gross Profit
For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mallinckrodt's Gross Profit Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Gross Profit distribution charts can be found below:
* The bar in red indicates where Mallinckrodt's Gross Profit falls into.
Mallinckrodt Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Mallinckrodt's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $356 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mallinckrodt had a gross margin of 30.34% for the quarter that ended in Sep. 2023 => Competition eroding margins
Mallinckrodt Gross Profit Related Terms
Thank you for viewing the detailed overview of Mallinckrodt's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MCKPF has been successfully added to your 